United States Securities and Exchange Commission · EDGAR Accession 0001665160-25-001223

Form C/A

Offering Statement Amendment — Regulation Crowdfunding
Campaign file 020-35469
Issuer CIK 2051498
Raising via StartEngine Primary, LLC

AlphaRose Therapeutics Inc.

CorporationDEIncorporated 2023Austin, TXalpharose.com
Nature of amendmentIssuer is extending their end date to August 28th, 2025, disclosing the acquisition of Alpha Anomeric SA, and disclosing the appointment of Lance Hirsch.
A

The Offering

as disclosed in this filing
Common Stock
$1.35
$19,999
$4,999,999
August 28, 2025
Expired 290 days ago
$0max $4,999,999

Target is 0% of the maximum. Over-subscriptions accepted.

B

Financial Condition

two fiscal years, as filed
Pre-revenueDebt / assets 201%1 employee
Line itemMost recent FYPrior FYΔ
Revenue00
Cost of goods sold00
Net income(625,253)0
Total assets614,4980
Cash & equivalents525,84549,990▲ 952%
Accounts receivable00
Short-term debt81,0980
Long-term debt1,151,0980
Taxes paid00

Figures in USD as reported by the issuer. Securities offered in all 50 states.

C

Campaign Timeline

file 020-35469 · all filings under this campaign
Loading campaign history…